Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

Conclusion The combination of gemcitabine, capecitabine and vandetanib is well tolerated at the recommended phase II dose of gemcitabine 1000 mg/m2 weekly for three consecutive weeks, capecitabine 850 mg/m2 BID days 1–21, and vandetanib 300 mg daily, every 28 days. This combination demonstrated promising activity in pancreaticobiliary cancers and further evaluation is warranted in these diseases. NCT00551096.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

THURSDAY, Nov. 14, 2019 -- Global burdens of colorectal cancer, pancreatic cancer, inflammatory bowel disease (IBD), and stomach cancer increased from 1990 to 2017, according to four studies published online Oct. 21 in The Lancet Gastroenterology...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Jang Park Although there have been several analyses for identifying cancer-associated pathways, based on gene expression data, most of these are based on single pathway analyses, and thus do not consider correlations between pathways. In this paper, we propose a hierarchical structural component model for pathway analysis of gene expression data (HisCoM-PAGE), which accounts for the hierarchical structure of genes and pathways, as well as the correlations among pathways. Specifically, HisCoM-PAGE focuses on the survival phenotype and identifies its associated pathways. Moreover, its application to real biological ...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
Authors: Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T Abstract The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in Halifax, Nova Scotia, 20-22 September 2018. Experts in radiation oncology, medical oncology, surgical oncology, and pathology who are invo...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Condition:   Pancreatic Cancer Interventions:   Drug: Atezolizumab;   Biological: RO7198457;   Drug: mFOLFIRINOX Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Neoplasms Pancreatic Intervention:   Other: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling Sponsors:   Judith Dixon-Hughes;   Cancer Research UK;   NHS Greater Glasgow and Clyde Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pancreatic Cancer Interventions:   Drug: Atezolizumab;   Biological: RO7198457;   Drug: mFOLFIRINOX Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Neoplasms Pancreatic Intervention:   Other: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling Sponsors:   Judith Dixon-Hughes;   Cancer Research UK;   NHS Greater Glasgow and Clyde Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackgroundPancreatic cancer induces parenchymal atrophy and duct dilation. The aim of this study was to evaluate whether these radiologic modifications are associated with outcomes.MethodsUpfront pancreaticoduodenectomy patients with available preoperative contrast enhanced CT scan imaging were retrospectively analyzed. Thickness of the pancreas, size of the main pancreatic duct (MPD), and distance of the tumor from the ampulla were assessed. A training cohort was selected, including short- (3 –12 months following surgery) and long-term (≥ 36 months) survivors. Identified survival determin...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
RAS protein activator like 2 (RASAL2) belongs to the RAS GTPase-activating protein family and plays an important role in several cancers, including ovarian cancer, nasopharyngeal carcinoma, malignant astrocytoma, renal cell carcinoma, bladder cancer, colorectal cancer, liver cancer, triple-negative breast cancer, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negati...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to assess the impact of TGR in neuroendocrine tumors (NETs) and potential clinical and therapeutic applications.Materials and Methods.Patients (pts) with advanced grade (G) 1/2 NETs from the pancreas or small bowel initiating systemic treatment (ST) or watch and wait (WW) were eligible. Baseline and follow‐up scans were retrospectively reviewed to calculate TGR at pretreatment (TGR0), first follow‐up (TGRfirst), and 3(±1) months of study entry (TGR3m).Results.Out of 905 pts screened, 222 were eligible. Best TGRfirst (222 pts) cutoff was 0.8 (area under the curve, 0.74). When applied to TGR3m (10...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Cancer Diagnostics and Molecular Pathology, Endocrinology, Gastrointestinal Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Pancreas | Pancreatic Cancer | Study | Toxicology | Xeloda